▶ 調査レポート

世界の腎臓病治療薬市場予測(~2028年):錠剤、カプセル、その他

• 英文タイトル:Global Kidney Disease Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが調査・発行した産業分析レポートです。世界の腎臓病治療薬市場予測(~2028年):錠剤、カプセル、その他 / Global Kidney Disease Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 / GIR-22E8871資料のイメージです。• レポートコード:GIR-22E8871
• 出版社/出版日:GlobalInfoResearch / 2022年5月
• レポート形態:英文、PDF、115ページ
• 納品方法:Eメール(2~3営業日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
腎臓病治療薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の腎臓病治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx%の成長率で成長すると予想されます。

腎臓病治療薬市場は種類と用途によって区分されます。2017年~2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・錠剤、カプセル、その他

用途別セグメントは次のように区分されます。
・慢性糸球体腎炎、腎症候群、慢性腎不全、腎臓結石、腎嚢胞腎(多発性嚢胞腎)、糖尿病性腎症、高血圧性腎症、紫斑病、ループス腎炎、小児腎疾患

世界の腎臓病治療薬市場の主要な市場プレーヤーは以下のとおりです。
・GlaxoSmithKline、Sanofi、Roche、Pfizer、AstraZeneca、Keryx Biopharmaceuticals、Kissei Pharmaceutical、AbbVie、Amgen、Teva Pharmaceutical Industries、Tianjin Tongrentang Group、Jiangxi Jimin Kexin Jinshuibao Pharmaceutical、Datong Liqun Pharmaceutical、Hebei Ruisen Pharmaceutical、Changxing Pharmaceutical、zhejiang Shengbokang Pharmaceutical

地域別セグメントは次の地域・国をカバーします。
・北米(米国、カナダ、メキシコ)
・ヨーロッパ(ドイツ、フランス、イギリス、ロシア、イタリア)
・アジア太平洋(日本、中国、韓国、インド、東南アジア、オーストラリア)
・南アメリカ(ブラジル、アルゼンチン、コロンビア)
・中東およびアフリカ(サウジアラビア、UAE、エジプト、南アフリカ)

本調査レポートの内容は計15章あります。
・第1章では、腎臓病治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な腎臓病治療薬メーカーの企業概要、2019年~2022年までの腎臓病治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な腎臓病治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年~2028年までの地域別腎臓病治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年~2028年までの腎臓病治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年~2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年~2028年までの主要地域での腎臓病治療薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および腎臓病治療薬の産業チェーンを掲載しています。
・第13、14、15章では、腎臓病治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報(企業概要、製品概要、販売量、価格、売上):GlaxoSmithKline、Sanofi、Roche、Pfizer、AstraZeneca、Keryx Biopharmaceuticals、Kissei Pharmaceutical、AbbVie、Amgen、Teva Pharmaceutical Industries、Tianjin Tongrentang Group、Jiangxi Jimin Kexin Jinshuibao Pharmaceutical、Datong Liqun Pharmaceutical、Hebei Ruisen Pharmaceutical、Changxing Pharmaceutical、zhejiang Shengbokang Pharmaceutical
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年:錠剤、カプセル、その他
・用途別分析2017年-2028年:慢性糸球体腎炎、腎症候群、慢性腎不全、腎臓結石、腎嚢胞腎(多発性嚢胞腎)、糖尿病性腎症、高血圧性腎症、紫斑病、ループス腎炎、小児腎疾患
・腎臓病治療薬の北米市場規模2017年-2028年:アメリカ、カナダ、メキシコ
・腎臓病治療薬のヨーロッパ市場規模2017年-2028年:ドイツ、イギリス、フランス、ロシア、イタリア
・腎臓病治療薬のアジア市場規模2017年-2028年:中国、日本、韓国、インド、東南アジア、オーストラリア
・腎臓病治療薬の南米市場規模2017年-2028年:ブラジル、アルゼンチン
・腎臓病治療薬の中東・アフリカ市場規模2017年-2028年:サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Kidney Disease Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Kidney Disease Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Chronic Glomerulonephritis accounting for % of the Kidney Disease Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Tablets segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Kidney Disease Drugs include GlaxoSmithKline, Sanofi, Roche, Pfizer, and AstraZeneca, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Kidney Disease Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Tablets
Capsule
Other
Market segment by Application can be divided into
Chronic Glomerulonephritis
Nephrotic Syndrome
Chronic Renal Failure
Kidney Stones
Renal Cyst (polycystic Kidney)
Diabetic Nephropathy
Hypertensive Nephropathy
Purpura Nephritis
Lupus Nephritis
Pediatric Kidney Disease
The key market players for global Kidney Disease Drugs market are listed below:
GlaxoSmithKline
Sanofi
Roche
Pfizer
AstraZeneca
Keryx Biopharmaceuticals
Kissei Pharmaceutical
AbbVie
Amgen
Teva Pharmaceutical Industries
Tianjin Tongrentang Group
Jiangxi Jimin Kexin Jinshuibao Pharmaceutical
Datong Liqun Pharmaceutical
Hebei Ruisen Pharmaceutical
Changxing Pharmaceutical
zhejiang Shengbokang Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Kidney Disease Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Kidney Disease Drugs, with price, sales, revenue and global market share of Kidney Disease Drugs from 2019 to 2022.
Chapter 3, the Kidney Disease Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Kidney Disease Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Kidney Disease Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Kidney Disease Drugs.
Chapter 13, 14, and 15, to describe Kidney Disease Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

1 Market Overview
1.1 Kidney Disease Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Kidney Disease Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Tablets
1.2.3 Capsule
1.2.4 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Kidney Disease Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Chronic Glomerulonephritis
1.3.3 Nephrotic Syndrome
1.3.4 Chronic Renal Failure
1.3.5 Kidney Stones
1.3.6 Renal Cyst (polycystic Kidney)
1.3.7 Diabetic Nephropathy
1.3.8 Hypertensive Nephropathy
1.3.9 Purpura Nephritis
1.3.10 Lupus Nephritis
1.3.11 Pediatric Kidney Disease
1.4 Global Kidney Disease Drugs Market Size & Forecast
1.4.1 Global Kidney Disease Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Kidney Disease Drugs Sales in Volume (2017-2028)
1.4.3 Global Kidney Disease Drugs Price (2017-2028)
1.5 Global Kidney Disease Drugs Production Capacity Analysis
1.5.1 Global Kidney Disease Drugs Total Production Capacity (2017-2028)
1.5.2 Global Kidney Disease Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Kidney Disease Drugs Market Drivers
1.6.2 Kidney Disease Drugs Market Restraints
1.6.3 Kidney Disease Drugs Trends Analysis
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 GlaxoSmithKline Details
2.1.2 GlaxoSmithKline Major Business
2.1.3 GlaxoSmithKline Kidney Disease Drugs Product and Services
2.1.4 GlaxoSmithKline Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Kidney Disease Drugs Product and Services
2.2.4 Sanofi Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Kidney Disease Drugs Product and Services
2.3.4 Roche Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Kidney Disease Drugs Product and Services
2.4.4 Pfizer Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Kidney Disease Drugs Product and Services
2.5.4 AstraZeneca Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Keryx Biopharmaceuticals
2.6.1 Keryx Biopharmaceuticals Details
2.6.2 Keryx Biopharmaceuticals Major Business
2.6.3 Keryx Biopharmaceuticals Kidney Disease Drugs Product and Services
2.6.4 Keryx Biopharmaceuticals Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Kissei Pharmaceutical
2.7.1 Kissei Pharmaceutical Details
2.7.2 Kissei Pharmaceutical Major Business
2.7.3 Kissei Pharmaceutical Kidney Disease Drugs Product and Services
2.7.4 Kissei Pharmaceutical Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 AbbVie
2.8.1 AbbVie Details
2.8.2 AbbVie Major Business
2.8.3 AbbVie Kidney Disease Drugs Product and Services
2.8.4 AbbVie Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Amgen
2.9.1 Amgen Details
2.9.2 Amgen Major Business
2.9.3 Amgen Kidney Disease Drugs Product and Services
2.9.4 Amgen Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Teva Pharmaceutical Industries
2.10.1 Teva Pharmaceutical Industries Details
2.10.2 Teva Pharmaceutical Industries Major Business
2.10.3 Teva Pharmaceutical Industries Kidney Disease Drugs Product and Services
2.10.4 Teva Pharmaceutical Industries Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Tianjin Tongrentang Group
2.11.1 Tianjin Tongrentang Group Details
2.11.2 Tianjin Tongrentang Group Major Business
2.11.3 Tianjin Tongrentang Group Kidney Disease Drugs Product and Services
2.11.4 Tianjin Tongrentang Group Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical
2.12.1 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Details
2.12.2 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Major Business
2.12.3 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Kidney Disease Drugs Product and Services
2.12.4 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Datong Liqun Pharmaceutical
2.13.1 Datong Liqun Pharmaceutical Details
2.13.2 Datong Liqun Pharmaceutical Major Business
2.13.3 Datong Liqun Pharmaceutical Kidney Disease Drugs Product and Services
2.13.4 Datong Liqun Pharmaceutical Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Hebei Ruisen Pharmaceutical
2.14.1 Hebei Ruisen Pharmaceutical Details
2.14.2 Hebei Ruisen Pharmaceutical Major Business
2.14.3 Hebei Ruisen Pharmaceutical Kidney Disease Drugs Product and Services
2.14.4 Hebei Ruisen Pharmaceutical Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Changxing Pharmaceutical
2.15.1 Changxing Pharmaceutical Details
2.15.2 Changxing Pharmaceutical Major Business
2.15.3 Changxing Pharmaceutical Kidney Disease Drugs Product and Services
2.15.4 Changxing Pharmaceutical Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 zhejiang Shengbokang Pharmaceutical
2.16.1 zhejiang Shengbokang Pharmaceutical Details
2.16.2 zhejiang Shengbokang Pharmaceutical Major Business
2.16.3 zhejiang Shengbokang Pharmaceutical Kidney Disease Drugs Product and Services
2.16.4 zhejiang Shengbokang Pharmaceutical Kidney Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Kidney Disease Drugs Breakdown Data by Manufacturer
3.1 Global Kidney Disease Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Kidney Disease Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Kidney Disease Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Kidney Disease Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Kidney Disease Drugs Manufacturer Market Share in 2021
3.5 Global Kidney Disease Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Kidney Disease Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Kidney Disease Drugs Market Size by Region
4.1.1 Global Kidney Disease Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Kidney Disease Drugs Revenue by Region (2017-2028)
4.2 North America Kidney Disease Drugs Revenue (2017-2028)
4.3 Europe Kidney Disease Drugs Revenue (2017-2028)
4.4 Asia-Pacific Kidney Disease Drugs Revenue (2017-2028)
4.5 South America Kidney Disease Drugs Revenue (2017-2028)
4.6 Middle East and Africa Kidney Disease Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Kidney Disease Drugs Sales in Volume by Type (2017-2028)
5.2 Global Kidney Disease Drugs Revenue by Type (2017-2028)
5.3 Global Kidney Disease Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Kidney Disease Drugs Sales in Volume by Application (2017-2028)
6.2 Global Kidney Disease Drugs Revenue by Application (2017-2028)
6.3 Global Kidney Disease Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Kidney Disease Drugs Sales by Type (2017-2028)
7.2 North America Kidney Disease Drugs Sales by Application (2017-2028)
7.3 North America Kidney Disease Drugs Market Size by Country
7.3.1 North America Kidney Disease Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Kidney Disease Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Kidney Disease Drugs Sales by Type (2017-2028)
8.2 Europe Kidney Disease Drugs Sales by Application (2017-2028)
8.3 Europe Kidney Disease Drugs Market Size by Country
8.3.1 Europe Kidney Disease Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Kidney Disease Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Kidney Disease Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Kidney Disease Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Kidney Disease Drugs Market Size by Region
9.3.1 Asia-Pacific Kidney Disease Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Kidney Disease Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Kidney Disease Drugs Sales by Type (2017-2028)
10.2 South America Kidney Disease Drugs Sales by Application (2017-2028)
10.3 South America Kidney Disease Drugs Market Size by Country
10.3.1 South America Kidney Disease Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Kidney Disease Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Kidney Disease Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Kidney Disease Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Kidney Disease Drugs Market Size by Country
11.3.1 Middle East & Africa Kidney Disease Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Kidney Disease Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Kidney Disease Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Kidney Disease Drugs
12.3 Kidney Disease Drugs Production Process
12.4 Kidney Disease Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Kidney Disease Drugs Typical Distributors
13.3 Kidney Disease Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer